Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rebecq

1 850 clinical trials in Rebecq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rebecq at a glance
1 850
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 850 trials in Rebecq

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Pasteur Inc.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atebimetinib
  • Sponsor:Immuneering Corp.

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Narcolepsy

Recruiting

Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pitolisant
  • Sponsor:Harmony Biosciences Management Inc.

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rebecq

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research aims to optimize medication management for individuals with functional dyspepsia and reflux-related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Medication De-prescribing Strategies

The research evaluates different approaches including on-demand usage and alternative treatments, aimed at improving patient care in primary healthcare settings.

02 Primary Care Medicine

Studies examining long-term medication management practices in primary care, with a focus on gastrointestinal disorders and symptom control. This research explores alternative treatment approaches for common digestive complaints.

  • Treatment Optimization
  • Alternative Therapy Evaluation
  • Patient-Centered Care

The research compares various therapeutic strategies to identify the most effective approach for managing chronic digestive conditions in primary care settings.

03 Clinical Therapeutics

Investigation into medication discontinuation strategies, focusing on long-term acid suppression therapy. This research evaluates the effectiveness of different approaches to reducing medication dependence while maintaining symptom control.

  • Therapeutic Alternative Assessment
  • Symptom Management
  • Treatment Efficacy Comparison

The study compares conventional dose reduction methods with newer therapeutic approaches to optimize patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.